Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.37 |
| ▸ | TACR1 | P25103 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.36 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.36 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | DRD5 | P21918 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | LIG1 | P18858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14403053 | 0.90 | ESR2 (0.42) | ESR2TACR1TRPV3IKBKETBK1 | |
| SCHEMBL13920734 | 0.81 | NPC1 (0.34) | RAB9ANPC1ALDH1A1TRPV3IKBKE | |
| SCHEMBL14117575 | 0.81 | ESR2 (0.41) | ESR2ALDH1A1L3MBTL1IKBKETBK1 | |
| SCHEMBL1399819 | 0.81 | IKBKE (0.40) | ESR2TACR1ALDH1A1L3MBTL1TRPV3 | |
| SCHEMBL8383556 | 0.81 | ESR2 (0.58) | ESR2ESR1 | |
| SCHEMBL7292956 | 0.81 | ESR2 (0.37) | ESR2TRPV3IKBKETBK1ESR1 | |
| SCHEMBL13832594 | 0.81 | POLB (0.44) | ESR2ALDH1A1DRD2 | |
| SCHEMBL14336757 | 0.81 | SLC18A3 (0.45) | TACR1ALDH1A1L3MBTL1IKBKETBK1 | |
| SCHEMBL22816650 | 0.81 | HTR2C (0.53) | TACR1KDM1A | |
| SCHEMBL8972310 | 0.81 | TRPV3 (0.39) | RAB9ANPC1ALDH1A1TRPV3IKBKE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4678641-A1 | QUINOLINONE COMPOUND AND NAPHTHYRIDINONE COMPOUND AND USE THEREOF | Shanghai Helioson Pharmaceutical Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| EP-4673431-A1 | HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | Novartis AG (CH) | 2026-01-07 | — | — | EP | disclosed |
| US-12129246-B1 | Hydroquinazoline derivatives for the treatment of a disease or disorder | NOVARTIS AG (CH) | 2024-10-29 | — | — | US | disclosed |
| US-20240336598-A1 | HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-10-10 | — | — | US | disclosed |
| WO-2024180499-A1 | HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS AG (CH) | 2024-09-06 | — | — | WO | disclosed |
| WO-2024149378-A1 | QUINOLINONE COMPOUND AND NAPHTHYRIDINONE COMPOUND AND USE THEREOF | 上海超阳药业有限公司 | 2024-07-18 | — | — | WO | disclosed |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2020257487-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| US-8729063-B2 | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2014-05-20 | — | — | US | disclosed |
| EP-1565436-A2 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004050024-A2 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2004-06-17 | — | — | WO | disclosed |
| US-6153611-A | AS NON-DOPAMINERGIC ANTIISCHEMIC COMPOUNDS FOR TREATING BRAIN DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-11-28 | — | — | US | disclosed |
| US-5595993-A | Antischemic piperazinyl- and piperidinyl-cyclohexanes | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-01-21 | — | — | US | disclosed |
| EP-0560669-B1 | Piperazinyl-and piperidinyl-cyclohexenes and cyclohexanes | BRISTOL MYERS SQUIBB CO (US) | 1995-06-14 | — | — | EP | disclosed |
| US-5352678-A | Dopaminergic agents | BRISTOL-MYERS SQUIBB CO. (US) | 1994-10-04 | — | — | US | disclosed |
| EP-0560669-A1 | Piperazinyl-and piperidinyl-cyclohexenes and cyclohexanes | Bristol-Myers Squibb Company (US) | 1993-09-15 | — | — | EP | disclosed |
| EP-0035902-B1 | 1-(4-ARYL-CYCLOHEXYL)PIPERIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1984-10-31 | — | — | EP | disclosed |
| US-4329353-A | ANTIEMETIC AND NEUROLEPTIC AGENTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 1982-05-11 | — | — | US | disclosed |
| EP-0035902-A1 | 1-(4-Aryl-cyclohexyl)piperidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1981-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12129246-B1 | Hydroquinazoline derivatives for the treatment of a disease or disorder | RECQL, NRAS, RAB1A | RAB9A 63/4885NPC1 570/4885ESR2 3779/4885 |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | RAB9A 3923/4885NPC1 1158/4885ESR2 4547/4885 |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | RAB9A 3923/4885NPC1 1158/4885ESR2 4547/4885 |
| US-20240336598-A1 | HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | RECQL, NRAS, RAB1A | RAB9A 63/4885NPC1 570/4885ESR2 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.